Strasbourg, France – October 28, 2014 – Polyplus-transfection SA, a privately-held company developing innovative technologies for molecular and cellular biology, and Blue Sky BioServices, a contract research organization (CRO) providing Gene Through Screen services for the pharmaceutical and biotechnology R&D market, today announce a non-exclusive, research and commercial license agreement. Polyplus has granted Blue Sky BioServices a licence to use Polyethylenimine (PEI) for in vitro transfection applications.
Blue Sky BioServices, has become the 17th sub-licensee, and the 4th CRO to acquire rights from Polyplus to use its PEI-mediated transfection applications for research and commercial purposes. Of the other international Polyplus sub-licensees, five are big pharma companies. Six are in located in North America, and 11 in Europe. The license provides Blue Sky BioServices with freedom to use this globally recognized high performance technology from Polyplus-transfection to generate transfected cells to produce proteins, viruses and antibodies.
Polyplus-transfection is the worldwide, exclusive licensee of PEI for transfection applications. Transfection with PEI has the advantages of increased ease of use, a heightened transfection efficiency and excellent viability in mammalian cell lines most frequently chosen by scientists working in protein, virus and antibody production.
Blue Sky enables researchers in life science companies to work more efficiently by utilizing Blue Sky’s expertise and technologies in gene synthesis, protein production and purification, and specialized assay services. Blue Sky collaborates with customers globally to rapidly produce complex proteins which are widely used in research and discovery applications for screening, assay and drug development. Blue Sky uses proprietary and best in class technologies, such as PEI, to improve the quality and speed with which it meets customers’ needs.
Financial terms were not disclosed.